| Novartis | |
|---|---|
| Blackstone, Carlyle Mull Joint Bid for Novartis Generics Arm | 2/1/2022 |
| Novartis Unwinds Roche Ties With $20.7 Billion Stake Sale | 11/3/2021 |
| Deutsche Bahn Said to Prepare $23 Billion Schenker Sale | 2/16/2022 |
| Novartis May Spin Off or Sell Ailing Sandoz Generics Unit | 10/25/2021 |
| Novartis Plans Up to $15 Billion Buyback With Roche Proceeds | 12/15/2021 |
| Novartis Has a Big Pile of Cash and Investors Wanting Action | 11/17/2021 |
| Novartis Said to Lean Toward Spinoff of $25 Billion Generics Arm | 6/30/2022 |
| Novartis Is Said to Pick BofA and UBS for Sandoz Sale, Spinoff | 10/25/2021 |
| Up 12-25% vs. March Low, European Safe Havens Stretch Valuations | 4/14/2022 |
| Mirati, Alnylam, Vertex Viewed as Top M&A Targets: BI Survey | 12/12/2021 |
| Novartis Sets Upbeat Pipeline Target as It Weighs Deals, Buyback | 12/1/2021 |
| *BLACKSTONE/CARLYLE SAID TO MULL JOINT BID FOR $25B NOVARTIS ARM | 2/1/2022 |
| Novartis Pushes Forward With Covid Drug After Positive Trial | 1/10/2022 |
| Novartis’s Sandoz Unit May Be a Tough Pill for Buyers to Swallow | 2/2/2022 |
| CORRECT: Novartis Sells Roche Stake to Roche for $388.99/Share | 11/3/2021 |
| Novartis to Cut as Many as 8,000 Jobs Under CEO’s Streamlining | 6/28/2022 |
| Novartis Plans $1 Billion Cost Savings Amid Pressure to Perform | 4/4/2022 |
| Biotech-Pharma Key Events Next Week, Part 2: PDUFA, FDA Panel | 10/5/2021 |
| Ark Funds Sell Tesla, Novartis; Buy UiPath, Signify Health | 9/27/2021 |
| Biotech-Pharma Key Events Next Week, Part 1: PDUFA, FDA Panel | 9/7/2021 |
AnalystSolutions respects your privacy and will never share your information with others. You can remove yourself from any distribution with one click.
We offer free full versions of our content for evaluation purposes (valued at over $700) to professionals holding the following roles:
You will receive:
To ensure a quick verification of your role above (usually within one business day), please provide the email address issued by your organization.
You will be directed to our 20-question quiz to determine if you possess the skills of a seasoned equity research analyst. Please provide a valid email address to receive your results (your email address remains confidential within AnalystSolutions):
We will attempt to reply to you within one business day based upon the responses to our questions below.
You will be directed to the FREE SAMPLE EDITION of our GAMMA PI™ Equity Research Analyst Self-Assessment. Please provide a valid email address to receive your results (your email address remains confidential within AnalystSolutions).
Please answer these questions to help James Valentine prepare for your call (he will keep your responses confidential):
Please answer these questions to help James Valentine prepare for your call (he will keep your responses confidential):
Please answer these questions to help James Valentine prepare for your call (he will keep your responses confidential)
Please answer these questions to help James Valentine prepare for your call (he will keep your responses confidential)